2361 ORIGINAL RESEARCH—ERECTILE DYSFUNCTION Dropout in the Treatment of Erectile Dysfunction with PDE5: A Study on Predictors and a Qualitative Analysis of Reasons for Discontinuation jsm_2787 2361..2369 Ana A. Carvalheira, PhD,* Nuno Monteiro Pereira, MD,...
More
2361 ORIGINAL RESEARCH—ERECTILE DYSFUNCTION Dropout in the Treatment of Erectile Dysfunction with PDE5: A Study on Predictors and a Qualitative Analysis of Reasons for Discontinuation jsm_2787 2361..2369 Ana A. Carvalheira, PhD,* Nuno Monteiro Pereira, MD, PhD,† João Maroco, PhD,* and Vera Forjaz, MSc* *Research Unit of Psychology and Health, University Institute of Applied Psychology, Lisbon, Portugal; † iSex—Association for the Advanced Study of Human Sexuality, ULHT, Lisbon, Portugal DOI: 10.1111/j.1743-6109.2012.02787.x ABSTRACT Introduction. Phosphodiesterase type 5 inhibitors (PDE5) are currently the first line treatment for erectile dysfunc- tion (ED). However, previous research shows that PDE5 treatments have high discontinuation rates. Understanding the reasons for discontinuing PDE5 will be necessary to optimize the response to treatment. Aim. The main goals were: (i) to analyze discontinuation rate of PDE5; (ii) to identify the discontinuation predictors; and (iii) to study
Less
